Ohio State University-ko ikertzaileekin lankidetzan egindako argitalpenak (34)

2024

  1. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future Oncology, Vol. 20, Núm. 13, pp. 799-809

  2. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Clinical Therapeutics, Vol. 46, Núm. 8, pp. 612-621

  3. PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

    The Journal of clinical investigation, Vol. 134, Núm. 3

  4. Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012

    Gynecologic Oncology, Vol. 189, pp. 68-74

  5. Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer–a plain language summary

    Future Oncology, Vol. 20, Núm. 22, pp. 1531-1544

2023

  1. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes

    Leukemia Research, Vol. 134

  2. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

    European Journal of Cancer, Vol. 189

2022

  1. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

    Therapeutic Advances in Medical Oncology, Vol. 14

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients with Osteosarcoma

    JAMA Oncology, Vol. 6, Núm. 5, pp. 724-734

  2. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

  3. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

    Gynecologic Oncology, Vol. 157, Núm. 2, pp. 379-385

  4. The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome

    Nature Cancer, Vol. 1, Núm. 11, pp. 1066-1081

2019

  1. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: Results from 3 UK clinical trials

    Blood Advances, Vol. 3, Núm. 16, pp. 2474-2481

  2. Niraparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402

2018

  1. A phase ii multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

    Haematologica, Vol. 103, Núm. 8, pp. 1351-1358

  2. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials

    JAMA Ophthalmology, Vol. 136, Núm. 6, pp. 666-677

  3. Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients

    International Journal of Cancer, Vol. 142, Núm. 8, pp. 1594-1601

  4. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

    Gynecologic Oncology, Vol. 151, Núm. 1, pp. 46-52

2016

  1. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

    Leukemia, Vol. 30, Núm. 11, pp. 2179-2186